Telephone Based Management of Hyperlipidemia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01212159|
Recruitment Status : Completed
First Posted : September 30, 2010
Results First Posted : September 25, 2015
Last Update Posted : September 25, 2015
|Condition or disease||Intervention/treatment||Phase|
|Hyperlipidemia||Device: Self Monitoring Lipid Analyzer||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||70 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Telephone Based Management of Hyperlipidemia Utilizing a Self Monitoring Testing Device|
|Study Start Date :||November 2010|
|Primary Completion Date :||July 2015|
|Study Completion Date :||August 2015|
No Intervention: No self monitoring device
Standard or usual care of high LDL including lab lipid profiles after treatment with statin therapy. No device or telemedicine education will be provided
Experimental: Self Monitoring Lipid Analyzer
Self measured blood lipids using a home lipidometer, and telephone reporting of data to the clinical center.
Device: Self Monitoring Lipid Analyzer
The device is similar to a glucometer- Utilizing a lancet a small amount of blood is collected in a capillary tube and placed on a hand held monitor that records lipid values.
Other Name: Cardiochek
- LDL Level Change From Baseline [ Time Frame: baseline to 6 months ]Comparison of serum LDL level between control and intervention subjects
- Medication Compliance [ Time Frame: 6 months ]Self reported comparison of lipid medication compliance between control and intervention subjects, scale 0-4. Highest compliance value indicated by a score of 4.
- LDL Values at Two Week Interval [ Time Frame: 6 weeks ]Participant in the self monitored arm reported LDL every two weeks. LDL goal for treatment was 100 mg/dl and subjects were followed every two weeks to observe mean LDL values.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01212159
|United States, Pennsylvania|
|Temple University Hospital|
|Philadelphia, Pennsylvania, United States, 19140|